The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > The Liposome Company, Inc.

The Liposome Company, Inc.
 PROFILE
The Liposome Company, bought in 2000 by Irish pharmaceutical firm Elan, develops and markets lipid- and liposome-based drugs for treating cancer and other illnesses. The company's first product, ABELCET, combats severe fungal infections in patients with weakened immune systems. The drug is sold in the US (about 80% of sales) and some two dozen other countries. Myocet, a treatment for metastatic breast cancer, is approved in Europe. Utilizing its liposomal technology, the company is also developing treatments for breast, prostate, lung, and other cancers; bromotaxane, a drug in development, may fight ovarian cancer. The Liposome Company is also working on a gene-based drug-delivery system.

 FINANCIAL OVERVIEW
Fiscal Year-End: December
1999 Sales (mil.): 86.20
1-Yr. Sales Growth: 17.3%
Employees: 306
Revenue per employee: $281,699.35

 KEY PEOPLE
• Charles A. Baker
    CEO
• Lawrence R. Hoffman
    CFO

 CONTACT INFO
1 Research Way
Princeton, NJ 08540
US
Phone: 609-452-7060
Fax: 609-452-1890
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001